The stock of Chiasma Inc (NASDAQ:CHMA) reached all time low today, Oct, 28 and still has $2.04 target or 13.00% below today’s $2.35 share price. This indicates more downside for the $55.91M company. This technical setup was reported by Barchart.com. If the $2.04 PT is reached, the company will be worth $7.27 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 111,379 shares traded hands. Chiasma Inc (NASDAQ:CHMA) has declined 68.73% since March 28, 2016 and is downtrending. It has underperformed by 73.45% the S&P500.
Analysts await Chiasma Inc (NASDAQ:CHMA) to report earnings on November, 10. They expect $-0.66 EPS, down 43.48% or $0.20 from last year’s $-0.46 per share. After $-0.83 actual EPS reported by Chiasma Inc for the previous quarter, Wall Street now forecasts -20.48% EPS growth.
Chiasma Inc (NASDAQ:CHMA) Ratings Coverage
Out of 3 analysts covering Chiasma (NASDAQ:CHMA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Chiasma has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Barclays Capital downgraded Chiasma Inc (NASDAQ:CHMA) on Monday, April 25 to “Equal-Weight” rating. The stock of Chiasma Inc (NASDAQ:CHMA) has “Overweight” rating given on Monday, August 10 by Barclays Capital. Cowen & Co initiated the stock with “Outperform” rating in Monday, August 10 report. The firm earned “Outperform” rating on Monday, August 10 by William Blair. William Blair downgraded the stock to “Market Perform” rating in Monday, April 18 report.
According to Zacks Investment Research, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA.”
More notable recent Chiasma Inc (NASDAQ:CHMA) news were published by: Marketwatch.com which released: “Chiasma’s stock plummets 54% premarket after FDA response letter” on June 18, 2015, also Prnewswire.com with their article: “Chiasma, Inc. Prices Initial Public Offering of Common Stock” published on July 15, 2015, Quotes.Wsj.com published: “Chiasma Inc. CHMA (US: Nasdaq)” on July 10, 2015. More interesting news about Chiasma Inc (NASDAQ:CHMA) were released by: Marketwatch.com and their article: “Chiasma to cut one-third of its workforce as part of restructuring” published on June 14, 2016 as well as Streetinsider.com‘s news article titled: “Form 4 CHIASMA, INC For: Oct 25 Filed by: Fitzpatrick Mark J.” with publication date: October 26, 2016.
CHMA Company Profile
Chiasma, Inc., incorporated on April 12, 2001, is a biopharmaceutical company. The Firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Firm has completed a Phase III clinical trial of its TPE platform product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.